Pulmatrix appoints Peter Ludlum as Interim CFO effective April 18, 2022

Pulmatrix, Inc.

Peter Ludlum appointed Interim CFO, Principal Accounting Officer, and Principal Financial Officer effective April 18, 2022.
Ludlum is a Danforth Advisors employee; services provided under consulting agreement at $400/hour.
Ludlum has 17 years C-level finance experience, previously CFO at Emmaus Life Sciences.
No family relationships or reportable transactions with Pulmatrix.
Appointment fills vacancy until a successor is chosen or earlier resignation/removal.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed (interim)

Peter Ludlum

Interim Chief Financial Officer

PULM · Pulmatrix, Inc.

Effective: 2022-04-18
Filed: April 15, 2022, 7:59 PM ET

On April 14, 2022, the Board of Directors of Pulmatrix, Inc. (the “Company”) appointed Peter Ludlum as Interim Chief Financial Officer of the Company, effective as of April 18, 2022, to serve until a successor is chosen and qualified, or until his earlier resignation or removal.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Peter Ludlum was appointed as Interim Chief Financial Officer at Pulmatrix, Inc..

Action: appointed
Role: Interim Chief Financial Officer

Exact text from the filing

On April 14, 2022, the Board of Directors of Pulmatrix, Inc. (the “Company”) appointed Peter Ludlum as Interim Chief Financial Officer of the Company, effective as of April 18, 2022, to serve until a successor is chosen and qualified, or until his earlier resignation or removal.

View on SEC.gov

Pulmatrix, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-22-010083

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.